<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7103910/results/search/disease/results.xml">
  <result pre="International0172-81721437-160XSpringer Berlin HeidelbergBerlin/Heidelberg pmcid: 71039104566 doi: 10.1007/s00296-020-04566-9 : Correspondence COVID-19," exact="rheumatic" post="diseases and immunosuppressive drugs: an appeal for medication adherence"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="novel coronavirus (SARS-CoV-2) outbreak has raised concerns among patients on" exact="chronic" post="immunosuppressive therapy because of immune response to virus perceived"/>
  <result pre="be lowered, possibly fuelling non-adherence behaviour. Indeed, high frequency of" exact="infection" post="has been observed in patients with rheumatic diseases. Despite"/>
  <result pre="high frequency of infection has been observed in patients with" exact="rheumatic" post="diseases. Despite immunosuppressive agents and impaired immune function had"/>
  <result pre="impaired immune function had been associated with increased risk of" exact="infection" post="[1, 2], it must be remembered that uncontrolled disease"/>
  <result pre="risk of infection [1, 2], it must be remembered that" exact="uncontrolled" post="disease activity is among the most sensitive and specific"/>
  <result pre="of infection [1, 2], it must be remembered that uncontrolled" exact="disease" post="activity is among the most sensitive and specific independent"/>
  <result pre="and specific independent predictors. To put research into context, for" exact="rheumatoid arthritis" post="patients it has been estimated that each 0.6 unit"/>
  <result pre="specific independent predictors. To put research into context, for rheumatoid" exact="arthritis" post="patients it has been estimated that each 0.6 unit"/>
  <result pre="it has been estimated that each 0.6 unit increase in" exact="Disease" post="Activity Score on 28 joints (DAS28) score corresponds to"/>
  <result pre="(DAS28) score corresponds to a 4% increased rate of outpatient" exact="infections" post="and a 25% increased rate of infections requiring hospitalisation"/>
  <result pre="rate of outpatient infections and a 25% increased rate of" exact="infections" post="requiring hospitalisation [3]. Similarly, those with systemic lupus erythematosus"/>
  <result pre="increased rate of infections requiring hospitalisation [3]. Similarly, those with" exact="systemic" post="lupus erythematosus (SLE) and SLE Disease Activity Index (SLEDAI)"/>
  <result pre="rate of infections requiring hospitalisation [3]. Similarly, those with systemic" exact="lupus erythematosus" post="(SLE) and SLE Disease Activity Index (SLEDAI) &amp;gt; 4 have"/>
  <result pre="[3]. Similarly, those with systemic lupus erythematosus (SLE) and SLE" exact="Disease" post="Activity Index (SLEDAI) &amp;gt; 4 have 71.5% higher odds of"/>
  <result pre="Activity Index (SLEDAI) &amp;gt; 4 have 71.5% higher odds of outpatient" exact="infection" post="[4]. Early in a pandemic, there is the paramount"/>
  <result pre="patient medication adherence to prevent arbitrary treatment discontinuation and consequent" exact="disease" post="flare leading to an increase of infection risk. As"/>
  <result pre="discontinuation and consequent disease flare leading to an increase of" exact="infection" post="risk. As a compelling argument in favour of medication"/>
  <result pre="of information about the impact of SARS-CoV-2 on patients with" exact="autoimmune" post="diseases. In the absence of such data, which we"/>
  <result pre="impact of SARS-CoV-2 on patients with autoimmune diseases. In the" exact="absence of" post="such data, which we all need to be published"/>
  <result pre="against arbitrary discontinuation of immunosuppressive agents by patients themselves unless" exact="symptomatic" post="and upon medical advice only. Publisher's Note Springer Nature"/>
  <result pre="ICMJE statement for each author. References References 1.IannoneFCantiniFLapadulaGDiagnosis of latent" exact="tuberculosis" post="and prevention of reactivation in rheumatic patients receiving biologic"/>
  <result pre="References 1.IannoneFCantiniFLapadulaGDiagnosis of latent tuberculosis and prevention of reactivation in" exact="rheumatic" post="patients receiving biologic therapy: international recommendationsJ Rheumatol Suppl201491414610.3899/jrheum.14010124788999 2.BarrettOAbramovichEDreiherJNovackVAbu-ShakraMShort-"/>
  <result pre="due to sepsis in patients with rheumatoid arthritisRheumatol Int20173761021102610.1007/s00296-017-3694-528286904 3.AuKReedGCurtisJRKremerJMGreenbergJDStrandVFurstDEInvestigatorsCHigh" exact="disease" post="activity is associated with an increased risk of infection"/>
  <result pre="3.AuKReedGCurtisJRKremerJMGreenbergJDStrandVFurstDEInvestigatorsCHigh disease activity is associated with an increased risk of" exact="infection" post="in patients with rheumatoid arthritisAnn Rheum Dis201170578579110.1136/ard.2010.12863721288960 4.DanzaARuiz-IrastorzaGInfection risk"/>
  <result pre="in patients with rheumatoid arthritisAnn Rheum Dis201170578579110.1136/ard.2010.12863721288960 4.DanzaARuiz-IrastorzaGInfection risk in" exact="systemic" post="lupus erythematosus patients: susceptibility factors and preventive strategiesLupus201322121286129410.1177/096120331349303224098001 5.ColsonPRolainJMLagierJCBrouquiPRaoultDChloroquine"/>
  <result pre="patients with rheumatoid arthritisAnn Rheum Dis201170578579110.1136/ard.2010.12863721288960 4.DanzaARuiz-IrastorzaGInfection risk in systemic" exact="lupus erythematosus" post="patients: susceptibility factors and preventive strategiesLupus201322121286129410.1177/096120331349303224098001 5.ColsonPRolainJMLagierJCBrouquiPRaoultDChloroquine and hydroxychloroquine"/>
 </snippets>
</snippetsTree>
